{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:53:56Z","timestamp":1791161636072,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019533","name":"Science Fund for Distinguished Young Scholars of Fujian Province","doi-asserted-by":"publisher","award":["2022J06027"],"award-info":[{"award-number":["2022J06027"]}],"id":[{"id":"10.13039\/501100019533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008021","name":"Fujian University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115275","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T17:32:58Z","timestamp":1690997578000},"page":"115275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-\u03baB signaling"],"prefix":"10.1016","volume":"165","author":[{"given":"En","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Wo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-ni","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115275_bib1","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.117.028728","article-title":"SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy","volume":"136","author":"Tang","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115275_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2023.115275_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00395-015-0501-x","article-title":"The Ca(2+)-activated cation channel TRPM4 is a negative regulator of angiotensin II-induced cardiac hypertrophy","volume":"110","author":"Kecsk\u00e9s","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.biopha.2023.115275_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbadis.2007.02.007","article-title":"Involvement of transient receptor potential proteins in cardiac hypertrophy","volume":"1772","author":"Guinamard","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2023.115275_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","article-title":"Cardiac hypertrophy: the good, the bad, and the ugly","volume":"65","author":"Frey","year":"2003","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.biopha.2023.115275_bib6","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1111\/jcmm.13645","article-title":"FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca(2+) \/calmodulin-mediated signalling pathways in vivo and in vitro","volume":"22","author":"Xiao","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2023.115275_bib7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1152\/japplphysiol.01383.2010","article-title":"Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes","volume":"111","author":"Lunde","year":"2011","journal-title":"J. Appl. Physiol. (1985)"},{"key":"10.1016\/j.biopha.2023.115275_bib8","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system","volume":"292","author":"Mehta","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.biopha.2023.115275_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.05.008","article-title":"AT1 receptor signaling pathways in the cardiovascular system","volume":"125","author":"Kawai","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2023.115275_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.019","article-title":"Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease","volume":"164","author":"Michel","year":"2016","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.115275_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/187153011795564133","article-title":"Functional relevance of biased signaling at the angiotensin II type 1 receptor","volume":"11","author":"Tilley","year":"2011","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.biopha.2023.115275_bib12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"Strauss","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115275_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.ajpath.2011.11.007","article-title":"The NF-\u03baB subunit c-Rel stimulates cardiac hypertrophy and fibrosis","volume":"180","author":"Gaspar-Pereira","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2023.115275_bib14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1083\/jcb.200207149","article-title":"Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy","volume":"159","author":"Gupta","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2023.115275_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/cvr\/cvq274","article-title":"Cardiomyocyte NF-\u03baB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure","volume":"89","author":"Hamid","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.115275_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lfs.2014.04.030","article-title":"NF-\u03baB-mediated integrin-linked kinase regulation in angiotensin II-induced pro-fibrotic process in cardiac fibroblasts","volume":"107","author":"Thakur","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.115275_bib17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbrc.2004.10.059","article-title":"ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression","volume":"325","author":"Schmeisser","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.115275_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/cvr\/cvp237","article-title":"NF-kappaB activation is required for adaptive cardiac hypertrophy","volume":"84","author":"Zelarayan","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.115275_bib19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.redox.2018.10.021","article-title":"Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload","volume":"20","author":"Chen","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2023.115275_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.118.037398","article-title":"Blood pressure-lowering by the antioxidant resveratrol is counterintuitively mediated by oxidation of cGMP-dependent protein kinase","volume":"140","author":"Prysyazhna","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115275_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/hr.2014.90","article-title":"Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA\/ROCK suppression in mice","volume":"37","author":"Cao","year":"2014","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2023.115275_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/cvr\/cvp285","article-title":"Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy","volume":"85","author":"Yue","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.115275_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1073\/pnas.97.2.931","article-title":"Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling","volume":"97","author":"Paradis","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.115275_bib24","first-page":"1049","article-title":"Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model","volume":"32","author":"Liu","year":"2005","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"10.1016\/j.biopha.2023.115275_bib25","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1039\/C9FO01075K","article-title":"The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease","volume":"10","author":"Hoseini","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.biopha.2023.115275_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/CIRCHEARTFAILURE.114.001677","article-title":"Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism","volume":"8","author":"Sung","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.biopha.2023.115275_bib27","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.787440","article-title":"Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1","volume":"119","author":"Dolinsky","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115275_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10557-022-07362-8","article-title":"NF-\u03baB, a potential therapeutic target in cardiovascular diseases","volume":"37","author":"Cheng","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2023.115275_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jmb.2007.10.006","article-title":"Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB","volume":"375","author":"Gupta","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2023.115275_bib30","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2003.07.021","article-title":"Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice","volume":"42","author":"Yamamoto","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115275_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yjmcc.2012.04.009","article-title":"CIKS (Act1 or TRAF3IP2) mediates angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy","volume":"53","author":"Valente","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2023.115275_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0076-6879(85)12037-9","article-title":"Osmotic delivery systems for research","volume":"112","author":"Fara","year":"1985","journal-title":"Methods Enzym."},{"key":"10.1016\/j.biopha.2023.115275_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100950","article-title":"Isolation, culture, and immunostaining of neonatal rat ventricular myocytes","volume":"2","author":"Pereira","year":"2021","journal-title":"STAR Protoc."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:07:40Z","timestamp":1777878460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223010661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"alternative-id":["S0753332223010661"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115275","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-\u03baB signaling","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115275"}}